Trial Profile
A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 04 Nov 2010 Results were presented at the 76th Annual Meeting of the American College of Chest Physicians: Chest 2010.
- 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.